Evaluation of Cerebrospinal Fluid Tau/beta-amyloid(42) Ratio As Diagnostic Markers for Alzheimer Disease

Overview

Journal Eur Neurol

Specialty Neurology

Date 2009 Sep 30

PMID 19786779

Citations 15

Authors

Mohamed Ali Smach

Bassem Charfeddine

Leila Ben Othman

Turkia Lammouchi

Hedi Dridi

Souhir Nafati

Afef Ltaief

Soufien Bennamou

Khalifa Limem

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD) is the leading cause of dementia. Currently, no definitive diagnostic test for AD exists. Cerebrospinal fluid (CSF) concentrations of amyloid beta (Abeta1-42) peptides and total tau proteins (T-tau) may serve as biomarkers for AD.

Aim: The objective of this study was to investigate the usefulness of CSF Abeta1-42 and T-tau analyses in the diagnosis of AD with Tunisians.

Methods: We focused on three groups originating from Central Tunisian that matched in age (range 48-85): healthy controls (n = 53), AD patients (n = 93) and non-Alzheimer (nAD) dementia (n = 35) patients. Abeta1-42 and T-tau levels were measured in CSF by sandwich enzyme-linked immunosorbent assay.

Results: The ratio of T-tau/Abeta1-42 at baseline yielded a sensitivity of 85.3% for detection of AD and the specificity was 84.8% to differentiate controls and nAD dementia.

Conclusion: Our findings confirm the use of T-tau/Abeta1-42 ratio in the discrimination of AD patients from all other patients.

Citing Articles

The Real-Time Validation of the Effectiveness of Third-Generation Hyperbranched Poly(ɛ-lysine) Dendrons-Modified KLVFF Sequences to Bind Amyloid-β Peptides Using an Optical Waveguide Light-Mode Spectroscopy System.

Perugini V, Santin M Sensors (Basel). 2022; 22(23).

PMID: 36502262 PMC: 9736926. DOI: 10.3390/s22239561.

Alzheimer disease's cerebrospinal fluid biomarkers differences between immigrants and natives in a Belgian memory clinic.

Lebrun L, Hanseeuw B, van Pesch V, Ivanoiu A Acta Neurol Belg. 2022; 123(2):537-544.

PMID: 36376773 DOI: 10.1007/s13760-022-02143-4.

Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer's Disease.

Fornari C, Mori F, Zoppi N, Libri I, Silvestri C, Cosseddu M Neurol Int. 2022; 14(2):357-367.

PMID: 35466210 PMC: 9036288. DOI: 10.3390/neurolint14020029.

Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease.

Hansson K, Dahlen R, Hansson O, Pernevik E, Paterson R, Schott J Clin Mass Spectrom. 2021; 14 Pt B:74-82.

PMID: 34917763 PMC: 8669449. DOI: 10.1016/j.clinms.2019.07.002.

Mitochondrial DNA and Alzheimer's disease: a first case-control study of the Tunisian population.

Ben Salem N, Boussetta S, de Rojas I, Moreno-Grau S, Montrreal L, Mokni N Mol Biol Rep. 2021; 49(3):1687-1700.

PMID: 34854014 DOI: 10.1007/s11033-021-06978-7.